Correction: Association between use of non-Vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation (JAMA - Journal of the American Medical Association (2017) 318:13 (1250-1259) DOI: 10.1001/jama.2017.13883);Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation

JAMA - Journal of the American Medical Association

Volumn 318, Issue 13, 2017, Pages 1250-1259

  Chang, Shang Hung ^a,b   Chou, I Jun ^a,b   Yeh, Yung Hsin ^a,b   Chiou, Meng Jiun ^a   Wen, Ming Shien ^a,b   Kuo, Chi Tai ^a,b   See, Lai Chu ^a,c   Kuo, Chang Fu ^a,b,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APIXABAN; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN; DIGOXIN; DILTIAZEM; DRONEDARONE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; VORICONAZOLE; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; EMERGENCY CARE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TAIWAN; THROMBOEMBOLISM; UROGENITAL BLEEDING; UROGENITAL TRACT DISEASE; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; EPIDEMIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POLYPHARMACY; PROPENSITY SCORE; STATISTICAL MODEL; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYPHARMACY; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TAIWAN;

EID: 85031329897     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.21113     Document Type: Erratum

References (42)

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.
2. Deedwania P, Acharya T. Anticoagulation in atrial fibrillation: is the paradigm really shifting? J Am Coll Cardiol. 2017;69(7):786-788.
3. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
4. Olesen JB, Sørensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2015;17(2):187-193.
5. Ruff CT, Giugliano RP, Antman EM. Management of bleeding with non-vitamin k antagonist oral anticoagulants in the era of specific reversal agents. Circulation. 2016;134(3):248-261.
6. Wang Y, Singh S, Bajorek B. Old age, high-risk medication, polypharmacy: a “trilogy” of risks in older patients with atrial fibrillation. Pharm Pract (Granada). 2016;14(2):706.
7. Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352-360.
8. Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868.
9. Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36(2):e5-e7.
10. Fralick M, Juurlink DN, Marras T. Bleeding associated with coadministration of rivaroxaban and clarithromycin. CMAJ. 188(9):669-672.
11. Delavenne X, Ollier E, Basset T, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol. 2013;76(1): 107-113.
12. Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591-1600.
13. Green B, Mendes RA, Van der Valk R, Brennan PA. Novel anticoagulants—an update on the latest developments and management for clinicians treating patients on these drugs. J Oral Pathol Med. 2016;45(8):551-556.
14. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34(27):2094-2106.
15. Chan Y-H, Yeh Y-H, See L-C, et al. Acute kidney injury in Asians with atrial fibrillation treated with dabigatran or warfarin. J Am Coll Cardiol. 2016;68 (21):2272-2283.
16. Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. BMJ. 2015;351:h6223.
17. Heidbuchel H, Verhamme P, Alings M, et al; Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary [published online June 9, 2016]. Eur Heart J. doi:10.1093/eurheartj/ehw058.
18. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009; 9(1):59-68.
19. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-466.
20. Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, Körnicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. 2012;52(2):243-250.
21. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175.
22. Wannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt DN. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation. 2014;98(2):e12-e13.
23. Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos. 2014;42(2):257-263.
24. Chan Y-H, Kuo C-T, Yeh Y-H, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68(13):1389-1401.
25. Tamayo SG, Simeone JC, Nordstrom BL, et al. Risk factors for major bleeding in rivaroxaban users with atrial fibrillation. J Am Coll Cardiol. 2016;68 (10):1144-1146.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40 (5):373-383.
27. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
28. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116): 1151-1154.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
30. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937-2960.
31. Lip GYH, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc Score 1 in men, 2 in women) be anticoagulated? yes: even 1 stroke risk factor confers a real risk of stroke. Circulation. 2016;133(15):1498-1503.
32. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
33. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69(11):e71-e126.
34. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
36. Flaker G, Lopes RD, Hylek E, et al; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541-1550.
37. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43 (8):2149-2156.
38. Pandit AK, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand. 2016;134(1):22-28.
39. Jia W, Zhou L. Effect of 20 mg/day atorvastatin: recurrent stroke survey in Chinese ischemic stroke patients with prior intracranial hemorrhage. J Clin Neurol. 2013;9(3):139-143.
40. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006;151(5): 976.e1-976.e6.
41. Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351: h4052.
42. Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke. 2016;47 (2):441-449.